Experience with siponimod for treating patients with secondary progressive multiple sclerosis in the Moscow Region

Siponimod is a sphingosine-1-phosphate receptor modulator approved in most countries for the treatment of secondary progressive multiple sclerosis (SPMS) with activity. The EXPAND study showed that the drug effectively reduces disease activity at the peripheral level by preventing autoreactive immune cells from leaving the lymph nodes, as well as reducing neurodegeneration by limiting the development of central inflammation and promoting oligodendrocyte survival. To more fully assess the therapeutic effect of siponimod, it is necessary to analyse the efficacy and safety of the drug in real-world clinical practice.

Objective. To evaluate the effect of siponimod on disease activity and progression in patients with SPMS in real-world clinical practice.

Material and methods. A retrospective-prospective observational cohort study was conducted in real-world clinical practice, involving 162 patients receiving siponimod and monitored at the Centre for Multiple Sclerosis and Other Neuroimmunological Diseases (CMS), organised on the basis of the M.F. Vladimirsky Moscow Regional Scientific and Clinical Institute.

Results. In patients with active MS, stabilisation of the condition was observed in 76.7% of cases after 24 months. The number of exacerbations in SPMS decreased threefold with siponimod therapy. 86.7% of patients remained compliant with therapy in the second year. No adverse events requiring discontinuation of siponimod therapy for medical reasons were reported in the study group.

Conclusion. The results obtained demonstrate the high efficacy and favourable safety profile of siponimod and are consistent with data from clinical trials. Stabilisation of the condition, minimal side effects, oral administration and a convenient dosing regimen increase patient compliance when using this drug.

1. Goldenberg MM. Multiple sclerosis review. P T. 2012;37:175-84.

2. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006;5(4):343-54.

3. Clinical practice guidelines for multiple sclerosis. Available at: https://cr.minzdrav.gov.ru/view-cr/739_2

4. Bierhansl L, Hartung HP, Aktas O, et al. Thinking outside the box: non-canonical targets in multiple sclerosis. Nat Rev Drug Discov. 2022;21(8):578-600.

5. Baker D, Marta M, Pryce G, et al. Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine. 2017;16:41-50.

6. Zuo M, Wang AA, Gommerman JL. Follicle on the Roof: Tertiary Lymphoid Structures in Central Nervous System Autoimmunity. Immunol Rev. 2025;332(1):e70045.

7. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004;14(2):164-74.

8. Preziosa P, Pagani E, Meani A, et al. Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression. Neurol Neuroimmunol Neuroinflamm. 2022;9(2):e1139.

9. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020;133(12):1380-90.e2.

10. Yong HYF, Yong VW. Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis. Nat Rev Neurol. 2022;18(1):40-55.

11. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:355-60.

12. Gergely P, Nuesslein-Hildesheim B, Guerini D, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167:1035-47.

13. O’Sullivan C, Schubart A, Mir AK, et al. The dual S1PR1/S1PR5 drug BAF312 (siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016;13:31.

14. Gentile A, Musella A, Bullitta S, et al. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13:207.

15. Ward LA, Lee DS, Sharma A, et al. Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury. JCI Insight. 2020;5(1):e132522. doi: 10.1172/jci.insight.132522

16. Benedict RHB, Tomic D, Cree BA, et al. Siponimod and cognition in secondary progressive multiple sclerosis: EXPAND secondary analyses. Neurology. 2020;96:e376-e386.

17. Arnold DL, Fox R, Bar-Or A, et al. Effect of siponimod on cortical grey matter and thalamic volume in patients with secondary progressive multiple sclerosis – results of the EXPAND study. In: 35th ECTRIMS Congress; 11–13 September 2019; Stockholm, Sweden; 2019. P382.

18. Instructions for the medical use of Kiendra® (In Russ.). Available at: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=24823e95-0c35-4f8e-8b10ed32c3947292

19. Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12:756-67.

20. Ksiazek-Winiarek DJ, Szpakowski P, Glabinski A. Neural plasticity in multiple sclerosis: the functional and molecular background. Neural Plast. 2015;2015:307175.

21. Dahlke F, Arnold DL, Aarden P, et al. Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): age is a key contributor to presentation. Mult Scler. 2021;27:2062-76.